rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    BBLGW
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      BBLG Earnings Illustrate Opportunity
      Oct 27Yahoo FinanceBBLGBBLGW
      Bone Biologics shareholders approve board nominees and reverse stock split
      Sep 29Investing.comBBLGBBLGW
      Bone Biologics expands Australian trial to six hospital sites
      Sep 8Investing.comBBLGBBLGW
      Bone Biologics Expands Trial Sites

      Addition of three sites strengthens expectation to complete enrollment by year-end 2026BURLINGTON, MA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced that six hospital sites in Australia are now under agreement to participate in its first-in-human pilot clinical trial of NB1, the Company’s rhNELL-1-based bone graft product for spinal fusion. Th

      Sep 8Yahoo FinanceBBLGBBLGW
      Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

      BURLINGTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel. Jeff Frelick, Chief Executive Officer of Bone Biologics will hold one-on-one meetings with investors

      Sep 3Yahoo FinanceBBLGBBLGW

      This is the newest page. Registered accounts read further back.